Takara Bio Inc. began as the biomedical business unit of Takara Shuzo Co., Ltd. (now Takara Holdings Inc.).
Based on the Company’s mission – Contributing to the health of humankind through the development of revolutionary biotechnologies such as gene therapy – Takara Bio will focus on three business segments that utilize its core biotechnology and encourage broader expansion: the Bioindustry Business, the basis for stable earning providing research reagents, scientific instruments, and various contracted services to universities and companies around the world; the AgriBio Business, the segment being nurtured as the Company’s secondary profit-making business; the Gene Therapy Business, the segment that the Company views as the foundation for future growth developing and commercializing gene therapies for cancer.
Taking advantage of the Japanese government’s current strong support for the fields of regenerative medicine, Takara Bio will accelerate the development of new products in the fields, such as basic research utilizing stem cells and regenerative medicine and cell therapy research. Leveraging the technologies and expertise developed over the years in gene therapy and clinical development, Takara Bio aims to expand its CDMO (Contract Development and Manufacturing Organization) business by providing contracted services including GMP (Good Manufacturing Practice) production of biopharmaceuticals, and serving as a contracted partner for R&D in the core facility of the Center for Gene and Cell Processing in Kusatsu city, Shiga prefecture.
Takara Bio develops original research reagents, scientific instruments, and contracted research services that utilize new genetic and cell engineering technologies on a consistent basis, supporting biotechnology research and bioindustry around the world in fields that range from basic research to drug discovery and development.
EIA Kits, Monoclonal Antibodies, Purified Proteins, Synthetic Peptides.